119 related articles for article (PubMed ID: 33895924)
61. Chemotactic response of unicellular Tetrahymena to a leukocyte attractant peptide and its repellent derivative: evolutionary conclusions.
Kõhidai L; Kovács P; Csaba G
Cell Biol Int; 1994 Feb; 18(2):119-22. PubMed ID: 8019483
[TBL] [Abstract][Full Text] [Related]
62. Cellular delivery of doxorubicin mediated by disulfide reduction of a peptide-dendrimer bioconjugate.
Burns KE; Delehanty JB
Int J Pharm; 2018 Jul; 545(1-2):64-73. PubMed ID: 29709616
[TBL] [Abstract][Full Text] [Related]
63. Effects of organic and inorganic substances on the cell proliferation of L-929 fibroblasts and Tetrahymena pyriformis GL protozoa used for toxicological bioassays.
Sauvant MP; Pépin D; Grolière CA; Bohatier J
Bull Environ Contam Toxicol; 1995 Aug; 55(2):171-8. PubMed ID: 7579920
[No Abstract] [Full Text] [Related]
64. HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity.
Ulbrich K; Etrych T; Chytil P; Jelínková M; Ríhová B
J Control Release; 2003 Feb; 87(1-3):33-47. PubMed ID: 12618021
[TBL] [Abstract][Full Text] [Related]
65. Building up a QSAR model for toxicity toward Tetrahymena pyriformis by the Monte Carlo method: A case of benzene derivatives.
Toropova AP; Schultz TW; Toropov AA
Environ Toxicol Pharmacol; 2016 Mar; 42():135-45. PubMed ID: 26851376
[TBL] [Abstract][Full Text] [Related]
66. Insulin treatment affects the behaviour of Tetrahymena pyriformis and T. malaccensis.
Mugnaini D; Ricci N; Banchetti R; Kovàcs P
Cytobios; 1995; 81(325):87-95. PubMed ID: 7671642
[TBL] [Abstract][Full Text] [Related]
67. Structure-toxicity relationships for selected lactones to Tetrahymena pyriformis.
Schultz TW; Deweese AD
Bull Environ Contam Toxicol; 1999 Apr; 62(4):463-8. PubMed ID: 10094730
[No Abstract] [Full Text] [Related]
68. Modification of doxorubicin-induced cardiotoxicity: manipulation of the dosage schedule.
Yeung TK; Chakrabarti K; Wilding D; Hopewell JW
Hum Exp Toxicol; 2002 Nov; 21(11):607-14. PubMed ID: 12507256
[TBL] [Abstract][Full Text] [Related]
69. Transferrin Receptor Targeted Cellular Delivery of Doxorubicin Via a Reduction-Responsive Peptide-Drug Conjugate.
Li S; Zhao H; Mao X; Fan Y; Liang X; Wang R; Xiao L; Wang J; Liu Q; Zhao G
Pharm Res; 2019 Oct; 36(12):168. PubMed ID: 31654226
[TBL] [Abstract][Full Text] [Related]
70. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
[TBL] [Abstract][Full Text] [Related]
71. Poly(ADP-ribose) polymerase-2 depletion reduces doxorubicin-induced damage through SIRT1 induction.
Szántó M; Rutkai I; Hegedus C; Czikora Á; Rózsahegyi M; Kiss B; Virág L; Gergely P; Tóth A; Bai P
Cardiovasc Res; 2011 Dec; 92(3):430-8. PubMed ID: 21921080
[TBL] [Abstract][Full Text] [Related]
72. Ingestion, cytotoxicity, and early morphological effects of asbestos on Tetrahymena.
Hjelm KK
J Environ Pathol Toxicol Oncol; 1988; 8(7 Spec No):15-26. PubMed ID: 2849651
[TBL] [Abstract][Full Text] [Related]
73. Polymeric micelles encapsulating pH-responsive doxorubicin prodrug and glutathione-activated zinc(II) phthalocyanine for combined chemotherapy and photodynamic therapy.
Gao D; Lo PC
J Control Release; 2018 Jul; 282():46-61. PubMed ID: 29673646
[TBL] [Abstract][Full Text] [Related]
74. [The use of Tetrahymena pyriformis infusoria to determine the level of toxemia in patients].
Shtrapov AA; Khanevich MD; Irlina IS
Lab Delo; 1990; (8):72-4. PubMed ID: 1705612
[TBL] [Abstract][Full Text] [Related]
75. Liposomes co-encapsulating doxorubicin and glucoevatromonoside derivative induce synergic cytotoxic response against breast cancer cell lines.
Novais MVM; Gomes ER; Miranda MC; Silva JO; Gomes DA; Braga FC; Pádua RM; Oliveira MC
Biomed Pharmacother; 2021 Apr; 136():111123. PubMed ID: 33486211
[TBL] [Abstract][Full Text] [Related]
76. A lectin-like molecule is discharged from mucocysts of Tetrahymena pyriformis in the presence of insulin.
Kovács P; Müller WE; Csaba G
J Eukaryot Microbiol; 1997; 44(5):487-91. PubMed ID: 9304818
[TBL] [Abstract][Full Text] [Related]
77. Synthesis of cholesteryl doxorubicin and its anti-cancer activity.
Choi JS; Doh KO; Kim BK; Seu YB
Bioorg Med Chem Lett; 2017 Feb; 27(4):723-728. PubMed ID: 28129977
[TBL] [Abstract][Full Text] [Related]
78. Comparative toxicity of four microcystins of different hydrophobicities to the protozoan, Tetrahymena pyriformis.
Ward CJ; Codd GA
J Appl Microbiol; 1999 May; 86(5):874-82. PubMed ID: 10347882
[TBL] [Abstract][Full Text] [Related]
79. Effect of riboflavon analogs on the growth of Tetrahymena pyriformis.
Wallace WC; Holmlund CE
J Nutr; 1980 Oct; 110(10):2113-6. PubMed ID: 6775059
[TBL] [Abstract][Full Text] [Related]
80. Evidence for N-Terminal Myristoylation of Tetrahymena Arginine Kinase Using Peptide Mass Fingerprinting Analysis.
Motomura S; Suzuki T
Protein J; 2016 Jun; 35(3):212-7. PubMed ID: 27129461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
